Modern Medical AI

About the speaker

Associate Professor Zongyuan Ge has wide expertise in AI, Biomedical Engineering, Digital Health, and Medical AI Applications. He is the Founding Director of the Monash Medical AI group and the AI Director of the Monash Augmented Intelligence and Multimodal analytics for Health (AIM) lab, leading over 50+ talented PhD students, 6 research fellows and 6 tenured professors and lecturers. He has worked with clinical institutions such as Monash Health, the Alfred Health and Stanford Health Care the program has attracted grants of over $25M for his work. He is currently the Chief Scientist for the Monash-Airdoc Research Centre, a $3M+ incubator and investment fund, is responsible for developing CFDA, NMPA, TGA, CLASS III approved healthcare monitoring products. He holds 150+ academic publications in top journals such as The Lancet Digital Health, The British Medical Journal, JAMA Neurology, Nature Nanotechnology, and 20 patents. His work has been recognised by many international and national awards, including the 200 Most Qualified Young Researchers in Computer and Mathematics by the Scientific Committee of the Heidelberg Laureate Foundation, IBM Scientific Research Accomplishment Award, NVIDIA AI Fellowship, Agilent Thought Leader Program, the Australian Pattern Recognition Society (APRS) Early Career Researcher Award, “the highest award of artificial intelligence in China”–Wu Wenjun Award for Artificial Intelligence Science and Technology twice in 2019, 2022, and Monash Exceptional Achievement Award.

Talk abstract

His talk will define and motivate the problem of Medical AI Research, the challenges as well as recent progress at the Monash Medical AI Group. This includes component technologies such as deep learning, evaluation methodologies, human-ai interaction, and also end-to-end software-to-hardware systems for applications such as disease diagnosis, disease prediction and management, and treatment. The aim is to develop next-generation medical applications capabilities that reduce Australia’s increasingly burden of disease, and that enable transformation of Australia’s most important healthcare sectors through enhanced automation and medical AI technologies. Our research re-combines expertise in human stem cell biology, biomedical engineering, clinical research and artificial intelligence scientists. Our medical AI products have served millions of people in China, India, Japan, South Africa and Australia. According to the financial report, the revenue generated from the ophthalmology AI products A/Prof Ge’s team co-developed has generated 25 million dollars in revenue in 2022.